NovoCure Limited
NASDAQ:NVCRMedical - Instruments & Supplies
-$3.51 today
- Market cap
- $1.25B
- Beta
- 0.92
- P/E (TTM)
- -9.5
- EPS (TTM)
- -$1.52
Volume 1.41M
Average 1.52M
NVCR Goodwill
The premium paid for acquisitions above the fair value of the identifiable net assets acquired.
NovoCure LimitedNASDAQ: NVCR
Goodwill · Q1 FY2026 · quarter ended Mar 2026
Goodwill remains negative
Q1 FY2026 goodwill was $0, compared with $0 a year earlier.
Context
- Goodwill amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Goodwill increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Goodwill history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Goodwill | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Goodwill vs competitors
How NVCR compares with its peers on the latest reported figures
- NVCR's Mar 2026 goodwill of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
- Goodwill amounts to 0.0% of total assets for NVCR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.79M | +0.0% | +0.0% | 2.4% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NVCR) | $0 | +0.0% | +0.0% | 0.0% | |
Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 209.61M | 115.33M | 240.82M | 163.77M | 103.39M |
| Short-term Investments | 728.9M | 854.1M | 669.8M | 796.11M | 354.13M |
| Net Receivables | 97.41M | 106.03M | 77.11M | 102.07M | 115.35M |
| Inventory | 24.43M | 29.38M | 38.15M | 35.09M | 41.11M |
| Other Current Assets | 8.47M | 508K | 1.74M | 2.33M | 23.1M |
| Total Current Assets | 1.07B | 1.11B | 1.03B | 1.11B | 646.73M |
| Property, Plant & Equipment (Net) | 53.88M | 68.96M | 97.7M | 119.59M | 147M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.09M | 11.16M | 14.02M | 14.62M | 10.6M |
| Total Non-current Assets | 65.97M | 80.12M | 111.72M | 134.21M | 157.6M |
| Total Assets | 1.14B | 1.19B | 1.15B | 1.24B | 804.33M |
| Account Payables | 72.6M | 85.2M | 94.39M | 105.09M | 122.23M |
| Short-term Debt | 6.68M | 0 | 0 | 558.16M | 11.66M |
| Tax Payables | 5.8M | 8.66M | 9.13M | 0 | 0 |
| Deferred Revenue | 17.76M | 18.03M | 16.22M | 14.23M | 15.95M |
| Other Current Liabilities | 169K | 0 | 0 | 0 | 9.03M |
| Total Current Liabilities | 142.6M | 158.78M | 179.12M | 756.38M | 223.23M |
| Long-term Debt | 562.22M | 565.51M | 568.82M | 97.3M | 236.69M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 6.48M | 2.88M | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.71M | 4.55M | 8.28M | 6.96M | (37.71M) |
| Total Non-current Liabilities | 586.4M | 591.7M | 604.52M | 124.23M | 240.63M |
| Total Liabilities | 729M | 750.48M | 783.63M | 880.61M | 463.86M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (685.93M) | (778.46M) | (985.5M) | (1.15B) | (1.29B) |
| Accumulated OCI | (3.17M) | (2.43M) | (5.47M) | (5.5M) | (3.44M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 410.49M | 441.17M | 362.5M | 360.18M | 340.47M |
| Total Debt | 581.9M | 584.27M | 596.24M | 683.35M | 290M |
| Net Debt | 372.29M | 468.95M | 355.42M | 519.59M | 186.61M |
NovoCure Limited
NASDAQ:NVCR
Intrinsic Alpha fair value
Locked
Current Price
$10.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.